InvestorsHub Logo

georgejjl

03/28/17 8:50 PM

#176635 RE: F1ash #176633

Planned oral formulations of Brilacidin

“We have received excellent results, to date, in our Brilacidin IBD trial, both regarding objective scores and subjective assessments. The systemic absorption of Brilacidin has been minimal while still yielding compelling patient responses,” said Arthur P. Bertolino, MD, PhD, MBA, President and Chief Medical Officer at Cellceutix. “We’re getting exactly what we need from a proof-of-concept study—clear and strong signals both as to the safety and the efficacy of Brilacidin in treating IBD. These results will help guide the continued development of Brilacidin, including planned foam and oral formulations, for hard-to-treat chronic conditions like Ulcerative Colitis and Crohn’s Disease.”



http://www.cellceutix.com/press-release/2017/3/15/cellceutixs-phase-2-drug-candidate-brilacidin-emerging-as-a-potential-novel-non-biologic-therapy-in-treating-inflammatory-bowel-disease

Good luck and GOD bless,

George

TheHound

03/28/17 8:53 PM

#176636 RE: F1ash #176633

interesting. appreciate the info yo.